Bombay High Court Reprimands Maharashtra FDA for Procedural Violations

• The Bombay High Court reprimanded the Maharashtra FDA for high-handed and procedure-defying actions against commercial and pharmaceutical entities.
• The court specifically questioned the FDA's cancellation of Amazon Retail India's food business license while an appeal against its suspension was pending.
• Acting Chief Justice Ravindra Ghuge stated that it is a settled legal principle that such actions should not be taken during an appeal period.
• The bench warned the FDA that "shooting first and asking questions later" is unacceptable in law, urging judicious power exercise.
• The ruling underscores the critical importance of due process and adherence to legal protocols by regulatory bodies like the Maharashtra Food and Drug Administration.

The court delivered a clear warning to the food safety regulator, stating that a policy of "shooting first and asking questions later" is legally unacceptable.

The Bombay High Court has issued a stern reprimand to the Maharashtra Food and Drug Administration (FDA), specifically citing actions taken under Commissioner Tukaram Mundhe, for what it described as high-handed and procedure-defying conduct. These criticisms arose from several matters heard over multiple days, involving both commercial and pharmaceutical entities.

A key instance highlighted by the court on August 7 involved Amazon Retail India. The e-commerce giant had challenged the FDA's decision to cancel its food business license for its Bhiwandi warehouse. Senior advocate Venkatesh Dhond, representing Amazon, detailed how FDA officials visited the warehouse on June 24, subsequently suspending its license the very next day, June 25, without first issuing an improvement notice.

Crucially, while Amazon's appeal against this suspension was still pending, the Maharashtra FDA proceeded to issue a show-cause notice on July 1. Following this, the regulator moved to cancel Amazon's license entirely, despite the ongoing appeal process concerning the initial suspension. This sequence of events formed a central point of contention for the High Court.

The division bench, comprising Acting Chief Justice Ravindra Ghuge and Justice Gautam Ankhad, questioned the legality of the FDA's actions, particularly the cancellation of a license while an appeal against its suspension remained unresolved. Acting Chief Justice Ghuge emphasized that it is a settled legal principle that such drastic actions should not be taken during the period when an appeal is pending.

The court delivered a clear warning to the food safety regulator, stating that a policy of "shooting first and asking questions later" is legally unacceptable. While acknowledging and even commending the FDA's regulatory vigilance in various instances, the bench underscored the critical importance for authorities to exercise their powers judiciously and adhere strictly to established due process. This ruling provides a significant precedent regarding Bombay High Court Maharashtra FDA procedural violations.

This judicial intervention highlights the judiciary's role in ensuring that regulatory bodies, even when pursuing legitimate enforcement goals, do not bypass fundamental procedural safeguards. The court's remarks serve as a strong reminder to the Maharashtra Food and Drug Administration about the imperative of respecting legal protocols, especially concerning food business license cancellation in India.

The Bombay High Court's strong observations against the Maharashtra FDA's conduct, particularly its high-handed actions and disregard for due process, carry significant weight for regulatory bodies across the state. The ruling reinforces the principle that even in the pursuit of public safety, administrative actions must be procedurally sound and respect the rights of regulated entities. The specific reprimand of Tukaram Mundhe-led FDA underscores accountability at the leadership level for ensuring compliance with legal norms.

This judgment sets a precedent that can be leveraged by businesses challenging similar FDA high-handed actions in India. It reinforces the necessity for regulators to issue proper notices, allow for appeals, and refrain from taking irreversible steps while legal challenges are still active. The court's insistence on judicious power exercise is a critical check on potential overreach, ensuring that the Maharashtra Food and Drug Administration operates within the bounds of law and fairness.

This ruling provides a strong precedent for challenging Maharashtra FDA actions that bypass due process, such as immediate license suspension or cancellation without prior notice or while appeals are pending. Lawyers can leverage this to advise clients on their rights and challenge high-handed regulatory conduct, while compliance officers should review FDA actions against their entities for procedural compliance.

Source: Original reporting via Live Law